Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.61 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGFR | P43088 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010231 | 1.00 | PTGER4 (0.61) | PTGER4PTGER3PTGER1KDM4EMEN1 | |
| SCHEMBL1009212 | 0.93 | PTGER4 (0.71) | PTGER4PTGER3PTGER1PTGER2MGLL | |
| SCHEMBL1009213 | 0.93 | PTGER4 (0.71) | PTGER4PTGER3PTGER1PTGER2MGLL | |
| SCHEMBL12952657 | 0.92 | PTGER4 (0.59) | PTGER4PTGER3PTGER1KDM4EMEN1 | |
| SCHEMBL1013598 | 0.90 | PTGER4 (0.68) | PTGER4PTGER3PTGER1MAPK1PTGFR | |
| SCHEMBL1011637 | 0.90 | PTGER4 (0.68) | PTGER4PTGER3PTGER1MAPK1PTGFR | |
| SCHEMBL4502745 | 0.85 | PTGER4 (0.67) | PTGER4PTGER3PTGER1MAPK1PTGFR | |
| SCHEMBL4502747 | 0.85 | PTGER4 (0.67) | PTGER4PTGER3PTGER1MAPK1PTGFR | |
| SCHEMBL12952604 | 0.85 | PTGER4 (0.68) | PTGER4PTGER3PTGER1KDM4EABCB11 | |
| SCHEMBL20750009 | 0.84 | PTGER4 (0.55) | PTGER4PTGER3PTGER1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812387-B1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2011-01-05 | — | — | EP | claimed |
| EP-1812387-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| US-7101906-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-09-05 | — | — | US | claimed |
| WO-2006055481-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN , INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | claimed |
| EP-1812387-B1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1812387-B1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1812387-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7101906-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006055481-A1 | 2,3,4-SUBSTITUTED CYCLOPENTANONES AS THERAPEUTIC AGENTS | ALLERGAN , INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106088-A1 | 2,3,4-Substituted cyclopentanones as therapeutic agents | CYCS, CA6, COX6C | PTGER4 663/4885PTGER3 189/4885PTGER1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.